Anti-Ebola virus therapeutic antibody: Research advances / 国际药学研究杂志

ABSTRACT

Ebola virus (EBOV) is a virulent virus, which can cause the occurrence of EBOV hemorrhagic fever with the mortality of 50%-90% in human and non-human primate (NHP) animal. The biohazard level of Ebola is BSL-4, which is higher than that of AIDS and SARS (BSL-3). Since 2014, the EBOV has spread in West Africa and taken away thousands of lives. At present, the prevention or therapeutic drugs in research against EBOV include vaccines, small molecule drugs and antibodies. Antibodies are relatively safe and specific with fewer side effects. There have reports of several functional antibodies, including monoclonal antibodies 16F6, KZ52 and "antibody cocktails" such as MB-003, ZMAb and ZMapp, which have better efficacy than monovalent antibodies; in China, a similar antibody combination, MIL77, has also completed the preclinical studies for emergency use. In this paper, the development of the antiEbola therapeutic antibodies is reviewed.